Estrogens should not be initiated for the secondary prevention of coronary artery disease: A debate

Canadian Journal of Cardiology

Volumn 16, Issue SUPPL. E, 2000, Pages

  Hulley, Stephen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Coronary disease; Prevention; Women

Indexed keywords

ESTROGEN; GESTAGEN; LIPID;

BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPIDS; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0034242424     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. The Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
2. HERS Coordinating Center, UCSF Prevention Sciences Group. Final results of the HERS main trial. (February 24, 1999) http://www.keeptrack.ucsf.edu/hers2/HERSfindat.htm
3. The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA 1970;214:1303-13.
4. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg/day estrogen group. The Coronary Drug Project Research Group. JAMA 1973;226:652-7.